Open AccessPlasma long noncoding RNA IL‐7R as a prognostic biomarker for clinical outcomes in patients with acute respiratory distress syndrome
Author(s) -
Wan Bing,
Xu WuJian,
Xu WeiNan,
Zhan Ping,
Wu GuanNan,
Jin JiaJia,
Xi GuangMin,
Yin JiangTao,
Zhang Hao,
Chen YiKun,
Miao YingYing,
Wang Xiaoxia,
Xu YingKun,
Lv TangFeng,
Song Yong
Publication year - 2018
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.12717
Subject(s) - medicine , biomarker , acute respiratory distress , intensive care medicine , respiratory distress , distress , oncology , bioinformatics , clinical psychology , lung , surgery , genetics , biology
Background Long non‐coding RNAs (lncRNAs) regulate a variety of genes and biological processes. Lnc‐IL7R plays a considerable role in the regulation of inflammation, but its prognostic potential in acute respiratory distress syndrome (ARDS) has not been fully explained. In this study, the role of lnc‐IL7R as a potential biomarker in ARDS was examined. Objective Role of lnc‐IL7R as potential biomarker in ARDS. Methods LncRNA‐IL7R was isolated from the plasma of patients with ARDS and healthy controls and clinical indexes were obtained within 24 h after admission. The relative expression of lnc‐IL7R was obtained by quantitative real‐time PCR. The correlations between lnc‐IL7R and continuous variables in ARDS were tested using Spearman's coefficients. Results A total of 85 ARDS patients and 49 healthy controls were included. Plasma lnc‐IL7R was significantly down‐regulated in ARDS compared with the levels in healthy control individuals, especially in severe ARDS ( P < .01). The area under the curve (AUC) of lnc‐IL7R for ARDS diagnosis was 0.87 (sensitivity 75.3%, specificity 93.9%). The lnc‐IL7R levels were correlated with the severity of ARDS (ρ = −0.31, P = .0215), oxygenation index (ρ = 0.61, P < .001), APACHE II score (ρ = −0.04, P = .0230), CRP (ρ = −0.26, P = .0148) and WBC (ρ = −0.29, P = .0064). Lnc‐IL7R relative value ≥ 0.33 showed the lower 28‐day mortality in the patients with ARDS( P < .05).The survivors showed higher lnc‐IL7R level and lower APACHE II score, SOFA score and length of mechanical ventilation than in the non‐survivors ( P = .0109, P < .001, P < .001 and P = .017, respectively). Conclusions Lnc‐IL7R is a novel biomarker for the diagnosis of ARDS and predicts the severity of ARDS and 28‐day mortality in this patients cohort. Trial registration The study was registered with the Chinese Clinical Trial Registry (ChiCTR‐DOD‐16008657).